Estrogen-androgen antagonism in the regulation of epidermal growth factor in mouse submandibular salivary gland and kidneys.
To eludicate hormonal regulation of epidermal growth factor (EGF) concentration we studied the effects in adult female mice of ovariectomy and postovariectomy treatments with testosterone plus estradiol on the EGF concentrations in submandibular salivary gland (SMG), plasma, kidneys and urine. In the tissues, we also studied the location of EGF immunohistochemically and measured EGF mRNA. After ovariectomy, SMG EGF first decreased to one third of preovariectomy level. After postovariectomy day 10 it started to increase and reached by day 80 3.5-fold the preovariectomy level. Simultaneously, EGF mRNA increased. Testosterone treatment further strongly augmented the levels of both EGF mRNA and EGF. A small dose of estradiol counteracted slightly the mRNA effect of testosterone. After ovariectomy plasma EGF first increased 1.3-fold by day 10, then returned to the initial levels, and rose again 1.6-fold by day 80. Testosterone treatment induced a further 1.5-fold increase. Estradiol did not counteract this effect. Kidney EGF decreased 15% by postovariectomy day 20. This was preceded by a decrease in EGF mRNA from day 10 onwards. The EGF concentration recovered during the 80 days, but the EGF mRNA level stayed low. Testosterone treatment further reduced the levels of both EGF mRNA and EGF. This effect was counteracted by estradiol. Urine EGF increased after ovariectomy to a peak (1.7-fold) by day 40. It then returned to the preovariectomy levels by day 80. Testosterone treatment increased urinary EGF 1.9-fold; concomitant estradiol had no effect.
Tuomela
T
T
Children's Hospital, University of Helsinki Finland.
Miettinen
P
P
Viinikka
L
L
Perheentupa
J
J
D000726:Androgen Antagonists / Q000494:pharmacology; D000728:Androgens / Q000502:physiology*; D000818:Animals; D004815:Epidermal Growth Factor / Q000097:blood / Q000378:metabolism* / Q000652:urine; D004958:Estradiol / Q000494:pharmacology / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000494:pharmacology; D004967:Estrogens / Q000502:physiology*; D005260:Female; D007150:Immunohistochemistry; D007668:Kidney / Q000378:metabolism; D051379:Mice; D010052:Ovariectomy; D012333:RNA, Messenger / Q000378:metabolism; D012469:Salivary Glands / Q000378:metabolism*; D013363:Submandibular Gland / Q000378:metabolism*; D013739:Testosterone / Q000494:pharmacology / Q000627:therapeutic use
D000726:Androgen Antagonists; D000728:Androgens; D004965:Estrogen Antagonists; D004967:Estrogens; D012333:RNA, Messenger; D013739:Testosterone; D004958:Estradiol; D004815:Epidermal Growth Factor